Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9272566 | 1.00 | BPTF (0.70) | BPTFTSHRHSD11B1LMNAHTT | |
| SCHEMBL8749192 | 1.00 | BPTF (0.70) | BPTFTSHRHSD11B1LMNAHTT | |
| SCHEMBL8748855 | 1.00 | BPTF (0.70) | BPTFTSHRHSD11B1LMNAHTT | |
| SCHEMBL8749153 | 1.00 | BPTF (0.70) | BPTFTSHRHSD11B1LMNAHTT | |
| SCHEMBL2529216 | 1.00 | BPTF (0.70) | BPTFTSHRHSD11B1LMNAHTT | |
| SCHEMBL8749130 | 1.00 | BPTF (0.70) | BPTFTSHRHSD11B1LMNAHTT | |
| SCHEMBL8749014 | 0.98 | BPTF (0.72) | BPTFTSHRHSD11B1LMNAHTT | |
| SCHEMBL12204818 | 0.98 | BPTF (0.72) | BPTFTSHRHSD11B1LMNAHTT | |
| SCHEMBL2530415 | 0.87 | TSHR (0.55) | BPTFTSHRHSD11B1LMNAHTT | |
| SCHEMBL12216280 | 0.87 | TSHR (0.55) | BPTFTSHRHSD11B1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389505-B2 | Adamantane derivatives of AZA-crown ethers and their use in treatment of tumor | RUDJER BOSKOVIC INSTITUTE (HR) | 2013-03-05 | — | — | US | disclosed |
| US-8389505-B2 | Adamantane derivatives of AZA-crown ethers and their use in treatment of tumor | RUDJER BOSKOVIC INSTITUTE (HR) | 2013-03-05 | — | — | US | disclosed |
| US-20110257254-A1 | Adamantane Derivatives Of Aza-Crown Ethers And Their Use In Treatment Of Tumor | RUDJER BOSKOVIC INSTITUTE (HR) | 2011-10-20 | — | — | US | disclosed |
| US-20110257254-A1 | Adamantane Derivatives Of Aza-Crown Ethers And Their Use In Treatment Of Tumor | RUDJER BOSKOVIC INSTITUTE (HR) | 2011-10-20 | — | — | US | disclosed |
| EP-0599928-B1 | STABILIZED COMPLEX LIGANDS AND THEIR USE IN LIQUID CRYSTAL DISPLAYS | HOECHST AG (DE) | 1997-03-19 | — | — | EP | disclosed |
| US-5445762-A | Stabilized complex ligands and their use in liquid crystal displays | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-29 | — | — | US | disclosed |
| EP-0599928-A1 | STABILIZED COMPLEX LIGANDS AND THEIR USE IN LIQUID CRYSTAL DISPLAYS. | HOECHST AG (DE) | 1994-06-08 | — | — | EP | disclosed |
| WO-1993004142-A1 | STABILIZED COMPLEX LIGANDS AND THEIR USE IN LIQUID CRYSTAL DISPLAYS | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-03-04 | — | — | WO | disclosed |
| EP-0528415-A1 | Stabilized complex ligands and their use in liquid crystal displays | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257254-A1 | Adamantane Derivatives Of Aza-Crown Ethers And Their Use In Treatment Of Tumor | CASP6, CDA, CASP8 | BPTF 4786/4885TSHR 859/4885HSD11B1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.